Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Want to cut your energy bills? Here’s how five experts are doing it 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
FREMONT, Calif., March 21, 2016 -- Zosano Pharma Corporation (NASDAQ:ZSAN) today announced that it plans to report financial results for the fourth quarter and full year 2015 on Tuesday, March 29, 2016. Zosano will host a conference call and webcast to provide a corporate update at 4:30 p.m. ET (1:30 p.m. PT) that day. The call will be hosted by Konstantinos Alataris, Ph.D., President and CEO, and Winnie W. Tso, CFO.
To participate via live webcast, please enter this event link on your web browser: http://edge.media-server.com/m/p/7md8rj2v.
To participate on the live call, please dial +1 (866) 410-5537 (domestic) or +1 (704) 908-0329 (international), and provide the conference ID 55587751, approximately 5 to 10 minutes ahead of the start of the call.
About Zosano Pharma
Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company that has developed a proprietary transdermal microneedle patch system to deliver drug formulations through the skin for the treatment of a variety of indications. Zosano Pharma's microneedle patch system offers rapid onset, consistent drug delivery, improved ease of use and room-temperature stability, benefits that the company believes often are unavailable using oral formulations or injections. Zosano Pharma's microneedle patch system has the potential to deliver numerous medications for a wide variety of indications in commercially attractive markets. It has been tested in more than 400 patients with over 30,000 patches successfully applied to humans in Phase 1 and Phase 2 clinical studies. Learn more at www.zosanopharma.com.
Zosano Contact:. Konstantinos Alataris, Ph.D. Chief Executive Officer 510-745-1200 Investor Contact: Patti Bank Westwicke Partners 415-513-1284 [email protected] Media Contact: Jamie Lacey-Moreira 410-299-3310 [email protected]
